White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Show more
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Sanofi (0A2V) currently trades at $39.79, while our model-based Fair Value estimate is $62.06, implying the stock looks roughly 35.9% undervalued today.
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($2.16 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$34.16
$51.46
$75.86
77
Growth DCF
$34.91
$50.51
$71.37
75
Owner Earnings
$47.40
$70.84
$103.93
73
All 26 models by family
DCF Models
FCF DCF
$34.16
$51.46
$75.86
77
Owner Earnings
$47.40
$70.84
$103.93
73
5Y Revenue Exit
$33.21
$53.06
$77.85
69
5Y EBITDA Exit
$48.96
$81.75
$119.20
71
5Y P/E Exit
$40.81
$66.90
$93.52
67
10Y Revenue Exit
$32.14
$49.86
$72.52
64
10Y EBITDA Exit
$42.92
$69.05
$102.61
65
10Y P/E Exit
$37.90
$59.12
$83.92
61
Earnings-Based
Graham-Dodd
$24.58
$66.43
$87.02
62
Lynch FV
$13.03
$18.61
$24.20
58
PEG = 1.0
$13.03
$18.61
$24.20
55
EPV
$28.83
$33.87
$38.21
71
Dividend Discount
Gordon GGM
$19.39
$38.63
$58.50
64
DDM Multi-Stage
$19.39
$29.72
$40.26
64
Multiples
P/E Multiple
$54.21
$72.28
$90.35
63
P/S Multiple
$40.52
$54.02
$67.53
58
P/B Multiple
$46.08
$61.44
$76.80
55
EV/EBIT
$56.88
$76.86
$96.83
66
EV/EBITDA
$65.84
$88.81
$111.77
67
EV/Revenue
$34.77
$50.97
$67.18
53
Asset-Based
NCAV (Graham)
$16.51
$22.12
$33.02
54
Growth DCF
Growth DCF
$34.91
$50.51
$71.37
75
Rev-Margin DCF
$33.21
$53.31
$75.61
69
Economic Profit
Residual Income
$29.50
$32.95
$41.15
73
ROIC Compounder
$28.83
$34.26
$42.11
69
Growth Earnings
Growth-Adj P/E
$42.97
$61.39
$79.81
65
Open the full fair value analysis →
Overall quality
72/100
Of which business quality 69
· Market factors (momentum, volatility) 45
Profitability
46
Margins and returns on capital today
Quality Growth
60
Are margins and returns improving?
Cashflow
65
Earnings quality: real cash, not paper profit
Fin. Strength
73
Balance sheet, leverage, solvency risk
Investment
90
Disciplined investing over empire-building
Low Volatility
91
Calm price path (market factor)
Momentum
34
Price trend over the last 3–12 months (market factor)
52W Momentum
11
Distance to the 52-week high (market factor)
Net Issuance
99
Share count: buybacks or dilution?
Open the full quality analysis →
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Pick a strategy and jump into the live analysis with that exact screen applied.
Is Sanofi (0A2V) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $62.06 versus a price of $39.79, about +56% upside (undervalued).
What is the fair value of 0A2V?
Our model-based fair value for Sanofi is $62.06 (as of Sep 24, 2026), built from audited fundamentals. The current price: $39.79.
What is the quality score of 0A2V?
Sanofi has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sanofi (0A2V)?
Our model-based price target is the fair value of $62.06 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $39.68, optimistic scenario $80.68. It is a calculation from audited fundamentals, not an analyst target.
What is the Sanofi stock forecast for 2026?
Our models put fair value at $62.06, about +56% upside versus a price of $39.79 (undervalued). Cautious scenario $39.68, optimistic scenario $80.68. The calculation is refreshed regularly with new filings.
What is the revenue of Sanofi (0A2V)?
Sanofi reported trailing-twelve-month revenue of about €47.4B (latest available figure, as of Sep 24, 2026).
What growth is priced into Sanofi (0A2V)?
For today's price to be fair in a discounted-cash-flow model, Sanofi would have to grow free cash flow by -9.9 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +4.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0A2V use?
Our models discount Sanofi at 9.0 %: a base by market capitalisation (unknown), damped by beta 0.28, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sanofi that is -9.9 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Sanofi (0A2V) delivered so far?
Over the past 4 years revenue at Sanofi grew +4.5 % a year. The price currently implies -9.9 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Sanofi (0A2V)?
The free-cash-flow yield on the price is 16.90 %: that much free cash flow Sanofi produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sanofi (0A2V)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanofi it is $62.06 per share (as of Sep 24, 2026), against a price of $39.79. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Sanofi stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0A2V trades below its calculated fair value: price $39.79, fair value $62.06, a gap of about +56% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0A2V?
No. The price is what the market pays today ($39.79); the fair value is what the company's own numbers justify ($62.06). For Sanofi the two are $22.27 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sanofi worth?
The market values Sanofi at about $48.1B (market capitalisation, as of Sep 24, 2026). Per share that is $39.79; our models calculate a fair value of $62.06 per share.
What do the bullish and bearish scenarios say about 0A2V?
Our models span a range for Sanofi: cautious scenario $39.68, base $62.06, optimistic $80.68 per share (as of Sep 24, 2026, price $39.79). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0A2V from its 52-week high?
Sanofi trades at $39.79, about 16% below its 52-week high of $47.62 and at the low of $39.65 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $62.06 is for.
Is Sanofi stock attractive at the current price?
The data as of Sep 24, 2026: price $39.79, calculated fair value $62.06 (+56%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0A2V calculated?
We run Sanofi through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $62.06, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Sanofi currently trades 36 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on
is it worth investing now.
What is the share price of Sanofi (0A2V)?
The closing price on Oct 2, 2026 was $39.79. Our model-based fair value is $62.06, about +56% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sanofi right now?
The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict. A fairly wide model range ($39.68 to $80.68) leaves room in how you read the outcome.
Key figures of Sanofi
How large is the market capitalisation of Sanofi (0A2V)?
The market capitalisation of Sanofi is $48.1B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Sanofi (0A2V)?
The price-to-earnings ratio of Sanofi is 0.1 (as of Jul 24, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Sanofi (0A2V)?
The price-to-sales ratio of Sanofi is 0.02 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sanofi (0A2V)?
Earnings per share at Sanofi are $2.86 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sanofi (0A2V)?
The net margin of Sanofi is 16.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sanofi (0A2V)?
The return on equity (ROE) of Sanofi is 6.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sanofi (0A2V)?
On an EBIT basis the return on assets of Sanofi is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sanofi (0A2V)?
The operating margin of Sanofi is 20.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sanofi (0A2V)?
Revenue at Sanofi is growing +6.0% versus a year earlier (3y avg +4.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sanofi (0A2V)?
Earnings per share at Sanofi are growing −11.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Sanofi (0A2V) carry?
The net debt of Sanofi is €10.9B (fiscal year 2025, ≈ 1.5 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
